Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

130
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
130
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

116
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
116
Tumor Immunotherapy01:27

Tumor Immunotherapy

457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

86
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
86

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and Validation of the ALARN Model: A Predictive Mortality Score for Antisynthetase Syndrome.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

A new hope with CAR T-cell therapy for refractory idiopathic inflammatory myopathies: a systematic review.

Journal of translational medicine·2026
Same author

Etiopathogenesis of Immune-Mediated Necrotizing Myopathy: A Comprehensive Review of Recent Advances.

CNS neuroscience & therapeutics·2026
Same author

Unsupervised clustering of clinical and laboratory features of systemic lupus erythematosus: insights from a multicentre cohort.

Lupus science & medicine·2026
Same author

Interferon-β Triggers Z-DNA Binding Protein 1-Mediated PANoptosis in T Cells of Anti-Melanoma Differentiation-Associated Protein 5 Antibody-Positive Dermatomyositis.

Immunology·2026
Same author

A serum biomarker-based index for predicting progressive pulmonary fibrosis in patients with anti-synthetase syndrome: the LOCCM index.

Respiratory research·2025

Related Experiment Video

Updated: May 23, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:49

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

59

Tocilizumab Monotherapy or Combined With Methotrexate for Rheumatoid Arthritis: A Randomized Clinical Trial.

Tian Liu1, Li Wang2, Xiao Zhang3

  • 1Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.

JAMA Network Open
|May 19, 2025
PubMed
Summary

Subcutaneous tocilizumab, alone or with methotrexate, significantly improved rheumatoid arthritis (RA) outcomes compared to methotrexate alone in a large Chinese trial. Tocilizumab demonstrated a favorable safety profile, offering a new treatment option for RA patients.

More Related Videos

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.0K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K

Related Experiment Videos

Last Updated: May 23, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:49

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

59
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.0K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K

Area of Science:

  • Rheumatology
  • Clinical Trials
  • Immunology

Background:

  • Rheumatoid arthritis (RA) patients often show inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).
  • Newer treatment options are crucial for managing RA effectively.
  • Comparative efficacy and safety data for subcutaneous tocilizumab (TCZ) monotherapy versus TCZ combined with methotrexate (MTX) and MTX monotherapy are limited.

Purpose of the Study:

  • To evaluate the efficacy and safety of subcutaneous TCZ monotherapy, TCZ-MTX combination, and MTX monotherapy in RA patients with an inadequate response to csDMARDs.

Main Methods:

  • A large-scale, double-blind, phase 3 randomized clinical trial conducted in China.
  • Adults (18-70 years) with moderate to severe active RA were randomized to TCZ-MTX, TCZ-placebo, or MTX-placebo for 24 weeks.
  • Primary efficacy endpoint was American College of Rheumatology 20% improvement (ACR20) at week 24; safety was monitored for 56 weeks.

Main Results:

  • Week 24 ACR20 response rates were significantly higher for TCZ-MTX (52.9%) and TCZ-placebo (50.0%) compared to MTX-placebo (25.0%).
  • Efficacy was maintained or improved during the 24-week extension phase for patients continuing TCZ-based treatments.
  • No new safety signals were identified for tocilizumab.

Conclusions:

  • Subcutaneous tocilizumab, as monotherapy or combined with methotrexate, is superior to methotrexate monotherapy for RA patients with inadequate csDMARD response.
  • Tocilizumab demonstrated a well-tolerated safety profile in this study population.
  • Further research in diverse ethnic and regional populations is recommended to confirm TCZ efficacy and safety, particularly as monotherapy.